Cytek Biosciences to Report Third Quarter Financial Results on November 8, 2021
Cytek Biosciences (Nasdaq: CTKB) announced it will release its third-quarter 2021 financial results on November 8, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cytek Biosciences (Nasdaq: CTKB) announced it will release its third-quarter 2021 financial results on November 8, 2021, after market close. A conference call will follow at 1:30 PM PT to discuss the results and future outlook. Cytek is recognized for its innovation in cell analysis technologies, specifically its Full Spectrum Profiling™ (FSP™) platform, which supports advanced cellular analysis through high-resolution and high-sensitivity tools. The company's offerings include the Aurora and Northern Lights systems, with products primarily for research use, except for limited clinical applications in China and the EU.
Positive
- Upcoming third-quarter earnings report expected on November 8, 2021.
- Management to host a conference call to discuss results and outlook.
- Innovation in cell analysis tools enhances competitive positioning.
Negative
- Products primarily restricted to research use, limiting revenue opportunities from clinical applications.
Details
News Market Reaction – CTKB
The recorded move for CTKB in the trading session of this news was -2.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2021 after market close on Monday, November 8th, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com
About Cytek Biosciences
Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems, its cell sorter, the Aurora CS, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe.
Other than Cytek’s Northern Lights CLC system, which is available for clinical use in China and the European Union, Cytek’s products are for research use only – not for use in diagnostic procedures or for clinical purposes.
Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.
Investor Relations Contact:
Carrie Mendivil/Mary Kate McDonough
Gilmartin Group LLC
investors@cytekbio.com
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.